PIK3CA and head and neck squamous cell carcinoma: Unfortunately, the efficacy of targeted therapies involving small molecule inhibitors of the EGFR/PI3K pathway has been limited due to the toxicity and possible drug resistance, raising the urgency of searching for other drug targets in the EGFR/PI3K signaling for more effective treatment of HNSCC patients [11, 12].